Today: 29 April 2026
Browse Category

NYSE:LAAC 6 October 2025

Lithium Americas (LAC) Soars as US Govt Takes 5% Stake – Analysts Weigh In on EV Lithium Boom

Lithium Americas (LAC) Soars on U.S. ‘White Gold’ Stake – Latest News, Stock Rally & Expert Outlook

Lithium Americas secured a $2.26 billion U.S. Department of Energy loan in October 2025 for its Thacker Pass lithium project, with the DOE and GM now holding equity stakes. LAC’s stock more than doubled in 2025, spiking 23% on news of the federal deal. The company remains pre-revenue, reporting a $13 million Q2 net loss but is fully funded for construction. Wall Street consensus rates the stock “Hold” with a $5.10 price target.

Stock Market Today

  • Peoples Bancorp (PEBO) Sees Share Price Momentum Amid Valuation Debate
    April 29, 2026, 9:20 AM EDT. Peoples Bancorp (PEBO) has gained investor focus following a robust share price rise, closing at $34.92. The Ohio-based regional bank, generating $424 million in annual revenue and $110 million in net income, holds a market value near $1.23 billion. Its recent returns include a 7.5% rise over one month and 15.8% year-to-date, with a 27.2% total shareholder return in one year, signaling growing momentum. Analysts place its intrinsic value around $37.17, about 6% above the current price, suggesting a modest undervaluation. Growth drivers include loan expansion, deposit growth, and strategic capital management. However, risks from credit costs and funding pressures may affect margins. Investors are advised to weigh these factors when considering PEBO amid a competitive community banking landscape.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop